ES3044110T3 - Apraglutide for use in the treatment of gastrointestinal graft versus host disease - Google Patents

Apraglutide for use in the treatment of gastrointestinal graft versus host disease

Info

Publication number
ES3044110T3
ES3044110T3 ES22705498T ES22705498T ES3044110T3 ES 3044110 T3 ES3044110 T3 ES 3044110T3 ES 22705498 T ES22705498 T ES 22705498T ES 22705498 T ES22705498 T ES 22705498T ES 3044110 T3 ES3044110 T3 ES 3044110T3
Authority
ES
Spain
Prior art keywords
apraglutide
subject
administered
approximately
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22705498T
Other languages
English (en)
Spanish (es)
Inventor
Violetta Dimitriadou
Nader N Youssef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectivbio AG
Original Assignee
Vectivbio AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectivbio AG filed Critical Vectivbio AG
Application granted granted Critical
Publication of ES3044110T3 publication Critical patent/ES3044110T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES22705498T 2021-01-28 2022-01-28 Apraglutide for use in the treatment of gastrointestinal graft versus host disease Active ES3044110T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142905P 2021-01-28 2021-01-28
US202163248074P 2021-09-24 2021-09-24
PCT/US2022/014349 WO2022165204A1 (en) 2021-01-28 2022-01-28 Compositions and methods for the treatment of graft versus host disease

Publications (1)

Publication Number Publication Date
ES3044110T3 true ES3044110T3 (en) 2025-11-26

Family

ID=80461100

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22705498T Active ES3044110T3 (en) 2021-01-28 2022-01-28 Apraglutide for use in the treatment of gastrointestinal graft versus host disease

Country Status (11)

Country Link
US (3) US20220233645A1 (https=)
EP (2) EP4635509A1 (https=)
JP (1) JP2024507324A (https=)
KR (1) KR20230167019A (https=)
AU (1) AU2022212119A1 (https=)
BR (1) BR112023014978A2 (https=)
CA (1) CA3206093A1 (https=)
ES (1) ES3044110T3 (https=)
IL (1) IL304675A (https=)
MX (1) MX2023008793A (https=)
WO (1) WO2022165204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025208047A1 (en) * 2024-03-28 2025-10-02 Vectivbio Ag Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8421271B2 (en) * 2009-08-31 2013-04-16 General Electric Company Apparatus for transferring energy using onboard power electronics and method of manufacturing same
EP2314616A1 (en) 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
EP3924369A1 (en) * 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs
KR20230038187A (ko) 2020-06-09 2023-03-17 벡티브바이오 에이지 아프라글루타이드의 제조, 제형화 및 투여

Also Published As

Publication number Publication date
IL304675A (en) 2023-09-01
JP2024507324A (ja) 2024-02-19
AU2022212119A1 (en) 2023-08-10
AU2022212119A9 (en) 2024-05-16
EP4635509A1 (en) 2025-10-22
BR112023014978A2 (pt) 2023-11-07
EP4284410A1 (en) 2023-12-06
CA3206093A1 (en) 2022-08-04
EP4284410B1 (en) 2025-07-02
WO2022165204A1 (en) 2022-08-04
US20240123036A1 (en) 2024-04-18
US20220233645A1 (en) 2022-07-28
US20240285730A1 (en) 2024-08-29
KR20230167019A (ko) 2023-12-07
MX2023008793A (es) 2024-02-15

Similar Documents

Publication Publication Date Title
ES2811367T3 (es) Análogos de éteres fosfolipídicos como vehículos de fármacos que seleccionan como objetivo el cáncer
JP2017516784A (ja) がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
CN105722852B (zh) 用于治疗口腔粘膜炎的新型肽和类似物
ES2922378T3 (es) C. novyi para el tratamiento de tumores sólidos en seres humanos
ES3044110T3 (en) Apraglutide for use in the treatment of gastrointestinal graft versus host disease
CN100409895C (zh) 用于治疗白血病和淋巴瘤的阿普立定组合
Sun et al. Dehydrocostus lactone alleviates irinotecan-induced intestinal mucositis by blocking TLR4/MD2 complex formation
US20080199478A1 (en) Combinations of Immunosupressive Agents for the Treatment or Prevention of Graft Rejections
WO2016130902A1 (en) Combination therapy using a cd19-adc and vincristine
CN117460523A (zh) 用于治疗移植物抗宿主病的组合物和方法
US8795738B2 (en) Use of arsenic for cancer therapy protection
HK40102861A (en) Apraglutide for use in the treatment of gastrointestinal graft versus host disease
HK40102861B (en) Apraglutide for use in the treatment of gastrointestinal graft versus host disease
EA051756B1 (ru) Композиции и способы лечения болезни "трансплантат против хозяина"
US10154989B2 (en) Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof
WO2025208047A1 (en) Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease
EP2707008A1 (en) Use of arsenic for cancer therapy protection
JP2006522060A5 (https=)
US8834938B2 (en) Use of arsenic for cancer therapy protection
ES2348077T3 (es) Combinaciones de agentes inmunosupresores para el tratamiento o la prevención del rechazo de injertos.
WO2007083985A1 (es) Composición farmacéutica sinergística de diclofenaco y clonixinato de lisina
HK40124218A (zh) 延长移植物和受体存活期的组合物和方法